About AMP®

Overview

The goal of the Accelerating Medicines Partnership® (AMP®) is to bring together the resources of NIH and industry to improve our understanding of disease pathways and facilitate better selection of targets for treatment. (Read the program description by NIH here.) Collaborations with 10 companies and three NIH Institutes have been established across five major disease areas: Alzheimer's disease, Type 2 diabetes, Rheumatoid Arthritis (RA)/Lupus, Parkinson's disease and Schizophrenia.

Partners

Private-Sector Partners:

• AbbVie* 
• Biogen*
• Bristol-Myers Squibb Company*
• Eli Lilly and Company*
• GlaxoSmithKline*
• Johnson & Johnson*
• Merck & Co., Inc.*
• Novartis Institutes for BioMedical Research*
• Pfizer Inc*
• Pharmaceutical Research and Manufacturers of America*
• Sanofi*
• Takeda Pharmaceuticals International, Inc.*
• UCB*

*Provided financial or in-kind support for this program.

Accelerating Medicines Partnership® Program - Alzheimer's Disease

Accelerating Medicines Partnership® Program - Common Metabolic Diseases